Replication defective adenoviruses are being considered of an E1-deleted recombinant that expresses the green as vectors in therapeutic applications of gene therapy, as fluorescent protein. Visualization of the cotransfection by well as research tools in studying gene function. Important fluorescent microscopy distinguishes recombinant plaques to their successful utilization is the development of tech-(nonfluorescent or 'white plaque') from background planiques to isolate new recombinants quickly, which are not ques (green fluorescent or 'green plaque'). Using this contaminated with wild-type virus. We describe a modifiapproach we have been able to increase substantially the cation of the traditional technique to create recombinant success and throughput for creating new recombinants adenoviruses in which a 5′ plasmid containing vector while minimizing contamination. This has been used to isosequence is cotransfected into 293 cells with viral DNA. In late adenoviral vectors deleted in a number of essential our protocol, the viral DNA is derived from the 3' portion genes.
Recombinant adenoviruses with insertions in the E1 region are traditionally produced by overlap recombination after cotransfection of 293 cells with a plasmid shuttle vector and a large right-end restriction fragment of viral DNA. 1 This shuttle vector typically contains a cassette for a transgene placed in region E1 and flanking sequences from adenovirus for recombination. A high background of parental virus results because of the difficulties in completely separating the right-end restriction fragment of adenoviral DNA from uncut DNA. In addition, mixed plaques can arise containing both parental and recombinant adenoviruses. This necessitates not only extensive screening of initial plaques but also laborious re-screening upon subsequent plaque purification.
Others have attempted to overcome these difficulties by using E. coli 2, 3 and yeast 4 DNAs instead of viral DNA. These systems lose the transfection efficiency attained with authentic viral DNA and are labor intensive requiring the isolation of an intact infectious clone of the desired vector in the shuttle system for each desired vector. Another strategy is to use a selection system, such as ␤-galactosidase as a negative selection system 5 or a parental vector expressing thymidine kinase coupled with the use of ganciclovir. 6 Finally, Cre-lox recombination has been recently described to accomplish the desired recombination in vitro. 7 We describe a negative selection system that is based on the traditional cotransfection method using viral DNA from a green fluorescent protein (GFP) expressing E1-
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Received 8 January 1998; accepted 16 March 1998 deleted adenoviral recombinant. In situ fluorescent microscopy distinguishes the recombinant plaques (nonfluorescent or white) from background (fluorescent or green) plaques which are derived from the parental virus. In addition, contamination with parental virus is easily detected at later stages when production lots of the recombinant adenovirus are being made.
The general strategy is to incorporate a simple and efficient screening method into the traditional cotransfection approach. Our previous experience with cotransfection in 293 cells is that the success rate is high and throughput is potentially fast. The problem is that the efficiency of homologous recombination to create a recombinant is often low compared with the background plaques that emerge from incompletely restricted parent viral DNA or religated viral DNA. Screening plaques by structural analysis of the viral DNA or expression of most transgenes requires isolation and characterization of individual plaques, which constitutes approximately 90% of the effort in isolating new recombinants. Furthermore, the plaques containing recombinant virus are often contaminated with the input virus requiring multiple rounds of plaque purification.
Our system overcomes the problem of screening by using an in situ fluorescence analysis of the initial plaques before isolation or subcloning. Ad5-based, E1-deleted adenovirus vectors expressing GFP were created and used as a source of 3′ viral restriction fragment. A CMVdriven GFP minigene was cloned in place of E1 with a unique ClaI site placed immediately 3′ to this minigene. GFP recombinants were created in a number of Ad5 backbones including: wild-type Ad5 (H5.000CMVEGFP); sub360 -200 bp deletion/insertion in E3b (H5.010CMV-EGFP); dl327 - and dl1004 -2.0 kb deletion of E4 removing everything but orf1 (H5.001CMVEGFP). In preparation for creating new recombinants, purified viral DNA was digested with ClaI and the large 3′ fragment was enriched by agarose gel electrophoresis or through a sucrose gradient.
The ClaI restricted 3′ viral DNA is mixed with the 5′ plasmid-based shuttle vector and cotransfected into 293 cells to create the recombinant by overlap recombination. The plate is overlaid with agar. Approximately 7-10 days later, the plate is visualized under an inverted microscope. If only a few plaques are present (ie 10-20), each is circled with a marker pen. The plate is then placed on the stage of an inverted fluorescent microscope and each plaque is observed, first using bright field and then using blue fluorescent light. If more than 20 plaques are seen, the plate is scanned directly using the microscope's lowest objective. Figure 1 shows a representative microscopic view under low magnification of a plate of 293 cells cotransfected with ClaI-digested H5.010CMVEGFP and pAdCMVhGH, an adenovirus shuttle plasmid that can express human growth hormone. Each plaque is clearly discerned as an area of discrete cytopathic effect when observed using bright light ( Figure 1a Figure 1c ) indicated that the right-most plaque is background (green fluorescent or 'green plaque') and only the two plaques on the left are potential recombinant adenoviruses expressing human growth hormone (nonfluorescent or 'white plaque'). This is referred to as green/white selection. The pure white plaques were picked for subsequent analysis and scaled-up. Five white plaques and one green plaque were isolated and used to infect 293 cells; the supernatants were analyzed for human growth hormone by ELISA. Growth hormone was detected in supernatants of all five white plaques but not from the green plaque ( Figure 2 ). Restriction analysis of viral DNA from the second white plaque confirmed its identity (Figure 2) .
Plaque purification can be repeated as many times as necessary using the green/white selection system, but it has been our experience that the first round of such purification yields a plate of secondary plaques often containing only white plaques. Therefore, if the density of these plaques is low in the initial transfection (eg less than 10 plaques on a 60-mm dish), usually no more than a single round of plaque purification is necessary. This substantially cuts down on the time of creating a new recombinant.
In the course of our studies we noted several interesting features of the cotransfection method that was not apparent using previous strategies for screening. Direct visualization using green/white selection demonstrated a high frequency of contaminated or mixed plaques. One problem is close juxtaposition of a green and white plaque that leads to cross contamination (Figure 3j-l) . In its extreme, this is manifested by 'fusion plaques' where an apparently symmetric plaque based on bright field is actually the fusion or overlap of a green and white plaque when viewed by fluorescence microscopy ( Figure 3a-c and d-f) . The frequency of fusion plaques increases with the density of total plaques on the plate. Another manifestation of contaminated plaques is shown in Figure 3g -i where one of the plaques is a mixture of green cells interspersed with white cells. This type of plaque occurs at a frequency that is independent of overall plaque density. We speculate that this represents cotransfection of two infectious viral DNA (ie a recombinant formed in the cell and residual parental viral DNA) in the same cell. Screening this plaque using the traditional approach would indicate the presence of the recombinant that would be difficult to purify whereas the c b a f e d i h g l k j
Figure 3 Examples of mixed plaques formed after transfection viewed using either bright field or fluorescence microscopy. Examples of different types of mixed plaques are shown including overlapping plaques (a-c and d-f), a mixed plaque with green and white cells interspersed (g-i), and plaques in close proximity to one another (j-l). Bright field, a, d, g and j; bright field and fluorescent, b, e, h and k; fluorescent, c, f, i and l. Original magnification is ×175.
isolate would be discarded using the green/white selection.
During the past year, we have made over 50 different recombinant adenoviruses using this system with an overall success rate of 80%; most of our failures have been explained by toxic transgenes. Table 1 summarizes our more recent experience with the green/white selection. A typical transfection using viral DNA from E1-or E1/E3-deleted constructs (ie H5000CMVEGFP, H5.010CMVEGFP and H5.030CMVEGFP) yields 100-200 plaques of which approximately 10% are white and 90% are either green or mixtures. This proportion of white to green plaques does vary although it is rarely greater than 20% despite exhaustive digestion of the parental virus DNA with ClaI and purification of the resulting digest. Essentially all white plaques are the desired recombinant when its genome size is Ͻ105% of wild type. The number of white plaques that are not the desired recombinants The structure of the adenoviral DNAs used to construct adenovirus vectors expressing GFP is listed below. Ad5 sub360 has a small deletion-insertion in region E3b that results in a net deletion of approximately 200 bp, whereas dl327 (obtained from Dr T Shenk, Princeton University) has an 1800 bp deletion in E3. Ad5 dl1004 9 has an extensive deletion in the E4 region (approximately 2.0 kb), removing all open reading frames except ORF1. The nomenclature for recombinant adenoviruses of the Institute for Human Gene Therapy at the University of Pennsylvania is followed 10 where H5 stands for human adenovirus type 5 and the next three numerals designate the structure of E2, E3 and E4 loci, respectively, followed by the promoter and transgene. H5.000CMVEGFP, H5.010CMVEGFP, H5.030CMVEGFP and H5.001CMVEGFP were constructed by overlap recombination of pAdCMVEGFP with ClaI-digested wild-type Ad5, Ad5 sub360, Ad5 dl327 and Ad5 dl1004, respectively. In some cases, the large right-end ClaI fragment was purified by sedimentation of the digest using a 5-20% sucrose gradient in 10 mm Tris-HCl (pH 7.4), 0.15 m NaCl and 1 mm EDTA for 3 h at 51 K in a Beckman Ti51 rotor. After collection of 0.5 ml fractions the right-hand restriction fragment was localized by agarose gel electrophoresis and recovered by precipitation with 2.5 volumes of ethanol.
Recombinant adenovirus are constructed by cotransfection of an adenovirus shuttle plasmid containing the transgene cassette of interest with one of the ClaI-digested adenoviral vectors described above. Transfections were done using either 293 cells 11 or in the case of viruses with a deletion in region E4, on dexamethasone treated 27-18 cells or Zn 2+ -treated 10-3 cells, each of which supply E4 function by inducible expression of ORF6.
12 Our standard method is described. Extreme care was taken to isolate GFP vectors void of any parental virus which would be replication competent virus. To obtain GFP vector DNA, 50 × 15-cm plates of 293 cells are infected with virus followed by collection of infected cells by centrifugation approximately 48 h later. The cells are lysed by three cycles of freezing and thawing. Adenovirus is purified from the clarified lysate by two cycles of banding on CsCl gradients and the final virus desalted by use of a gel filtration column. DNA is extracted from purified virions after treatment with SDS and proteinase K followed by phenol/chloroform/isoamyl alcohol extraction, chloroform/isoamyl alcohol extraction, and ethanol precipitation. The purified viral DNA (approximately 100 g) is cleaved by 16-18 h digestion with 10 U ClaI per g viral DNA at 37°C followed by addition of 1 U of ClaI per g DNA and an additional 2 h incubation at 37°C. Viral DNA is recovered by phenol/chloroform/isoamyl alcohol extraction followed by chloroform/isoamyl alcohol extraction of the aqueous phase. One-tenth volume of 3 m NaOAc (pH 5.2) is then added followed by 2.5 volumes of ethanol. The ClaI-digested viral DNA is recovered by centrifugation, washed with 1 ml of 70% ethanol and air-dried. The ClaI-digested vector DNA is dissolved in 10 mm Tris-HCl (pH 7.4), 1 mm EDTA and stored at 4°C. Transfections are performed using the calcium phosphate technique with a kit from Promega (Madison, WI, USA). Viral DNA (1 g) is mixed with plasmid DNA (10 g) and 37.5 l of 2 m CaCl 2 , and adjusted to a final volume of 300 l with water. This solution is then added dropwise to 300 l of Hepes-buffered saline solution while vortexing the Hepes-buffered saline. After standing for 30 min, 600 l of the precipitate is added dropwise to a 60-mm dish of 293 cells growing in DMEM with 10% fetal bovine serum that is approximately 70-80% confluent. The medium is changed on these dishes approximately 4 h before transfection. After overnight incubation the monolayer is washed with phosphate-buffered saline without calcium or magnesium followed by an agar overlay (5 ml) consisting of 1% agarose in MEM with 10% fetal bovine serum.
1 Dishes are overlaid with 3 ml of MEM with 10% fetal bovine serum/1% agarose every 3-4 days until plaques appear. The authenticity of isolates was determined by restriction enzyme analysis of Hirt DNA as well as by analysis of protein expression by either Western blot, Elisa, or radioimmunoassay. d Greater than 105% of wild-type genome.
decreases to 30-50% when the genome size is Ͼ105% of wild type or in the creation of E1-and E4-deleted vectors. 8 In summary, we describe a strategy for creating and screening recombinant adenoviruses that is fast, easily scaled-up, and capable of yielding stocks of vector that are free of parental virus contamination. The efficiency of adenoviral vectors for in vivo gene transfer is being exploited by the biopharmaceutical industry to assess gene function in the setting of functional genomics. Any modification that improves the scale and speed of creating recombinant viruses will impact directly on the number of genes that can be screened. The value of this system to gene therapy is in the isolation of recombinants void of contaminating parental virus. In situ visualization of the initial transfection using the green/white selection resulted in alarming number of 'recombinant plaques' that are contaminated with parental virus. It has been our experience that contamination in the original plaque is sometimes hard to detect and difficult to purge subsequently. The green/white selection is simply a way to help isolate recombinant adenoviruses subsequent to research and therapeutic applications.
